NCT07106671

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

A Prospective, Single-Arm, Single-Center, Phase II Clinical Trial of Siltuximab for Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity After CAR-T Treatment in Multiple Myeloma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.

Conditions

• CRS - Cytokine Release Syndrome
• Myeloma

Interventions

Type	Name	Description
DRUG	Siltuximab	Siltuximab 11mg/kg

Timeline

• Start date: 2025-08-10
• Primary completion: 2026-08-01
• Completion: 2027-08-01
• First posted: 2025-08-06
• Last updated: 2025-08-06

Locations

1 site across 1 country: China